Serological response to SARS-CoV-2 is attenuated in patients with inflammatory bowel disease and can affect immunization.
COVID‐19
anti‐SARS‐CoV2 antibodies
inflammatory bowel disease
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
17
11
2021
revised:
23
01
2022
accepted:
16
02
2022
entrez:
27
4
2022
pubmed:
28
4
2022
medline:
28
4
2022
Statut:
epublish
Résumé
In this study we indicated that impaired serological responses to SARS-CoV-2 infection among patients with IBD, could have significant implications for this group of patients and should be considered in vaccination program.
Identifiants
pubmed: 35475199
doi: 10.1002/jgh3.12725
pii: JGH312725
pmc: PMC9021711
doi:
Types de publication
Journal Article
Langues
eng
Pagination
266-269Informations de copyright
© 2022 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
J Can Assoc Gastroenterol. 2021 Jan 27;4(1):49
pubmed: 33644678
Gut. 2021 Apr;70(4):725-732
pubmed: 33082265
Pharmacol Res. 2020 Sep;159:104892
pubmed: 32464322
Inflamm Bowel Dis. 2021 Jan 1;27(1):25-33
pubmed: 32830267
Gut. 2021 May;70(5):865-875
pubmed: 33753421
JAMA Intern Med. 2020 Oct 1;180(10):1356-1362
pubmed: 32808970
J Clin Med. 2021 Aug 20;10(16):
pubmed: 34441985
Int J Infect Dis. 2020 Dec;101:220-225
pubmed: 33031941
Vaccine. 2012 Feb 14;30(8):1413-24
pubmed: 22197580
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):965-966
pubmed: 32971020
J Crohns Colitis. 2022 Mar 14;16(3):389-397
pubmed: 34473254